Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Bafna Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: BAFNAPH | BSE: 532989

₹304.25

up-down-arrow ₹13.15 (4.52%)

As on 31-Aug-2026IST

Market cap

info icon

₹720 Cr

Revenue (TTM)

info icon

₹143 Cr

P/E Ratio

info icon

92.5

P/B Ratio

info icon

7.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -37.07 -23.22 -3.14 0.52 13.48
EBIT -147.64 -124.30 -48.35 -28.16 -3.13
Net Profit -97.27 -97.79 -22.63 -21.86 5.00
EPS -97.27 -97.79 -5.78 -21.87 5.00
Book Value -- -- 13.38 9.39 11.11
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info ----3.706.484.10
Net Margin info ----5.247.142.79
Return on equity info ----8.31--5.01
Return on Capital info --------6.31
Return on Assets info ----4.74--2.76
Debt to Equity (x) info ----0.18--0.33

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
11.87
6.31
9.56
16.12
Peer Median
--
19.34
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

8.31

Lower than Peers by 7.04

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
8.31
12.27
5.01
9.52
16.75
Peer Median
15.35
16.97
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

4.74

Lower than Peers by 5.61

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
4.74
6.76
2.76
5.30
10.32
Peer Median
10.35
9.88
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

3.70

Lower than Peers by 14.30

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
3.70
6.48
4.10
4.01
9.00
Peer Median
18.01
18.96
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

5.24

Lower than Peers by 9.21

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
5.24
7.14
2.79
4.71
9.56
Peer Median
14.45
13.29
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
11.40
6.20
8.10
14.45
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-3.14

Lower than Peers by 15.09

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
-3.14
3.26
-4.33
32.18
35.48
Peer Median
11.95
12.97
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-48.35

Lower than Peers by 69.95

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
-48.35
62.98
-2.12
-41.09
61.93
Peer Median
21.60
15.05
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-22.63

Lower than Peers by 45.36

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
-22.63
167.30
-43.49
-35.19
117.34
Peer Median
22.73
11.89
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-5.78

Lower than Peers by 25.81

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
-5.78
167.31
-43.49
-35.19
117.34
Peer Median
20.03
12.16
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
13.38
4.91
10.05
18.54
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.18

Higher than Peers by 0.18

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
0.18
0.39
0.33
0.30
0.31
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
0.12
0.10
0.12
0.16
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.57

Lower than Peers by 0.52

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
1.57
1.57
1.63
1.73
1.88
Peer Median
2.08
1.93
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.06

Lower than Peers by 0.47

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
1.06
1.06
1.09
1.19
1.40
Peer Median
1.54
1.52
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

3.07

Lower than Peers by 16.30

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
3.07
4.00
2.52
4.21
6.70
Peer Median
19.38
19.95
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

30.81

Higher than Peers by 9.43

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
30.81
29.17
27.54
29.77
35.67
Peer Median
21.38
19.87
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.87

Higher than Peers by 0.15

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
0.87
0.92
0.97
1.10
1.05
Peer Median
0.72
0.77
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
101.91
107.07
103.59
88.49
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
69.05
72.23
62.08
67.24
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
138.54
149.66
134.43
118.26
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
32.41
29.64
31.24
37.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

92.49

Higher than Peers by 58.51

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
92.49
24.08
42.73
24.68
17.24
Peer Median
33.99
34.30
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

7.49

Higher than Peers by 2.43

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
7.49
2.78
2.09
2.24
2.66
Peer Median
5.06
5.19
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
--
--
--
--
--
Peer Median
0.49
0.50
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

42.38

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
42.38
14.62
14.53
13.96
11.09
Peer Median
--
30.46
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

720

Lower than Peers by 18,405

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Bafna Pharma
720
267
177
181
196
Peer Median
19,125
18,009
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...